Adage Capital Partners
ARQT icon

Adage Capital Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Adage Capital Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
466,000
+100,000
+27% +$2.33M 0.02% 674
2026
Q1 		$8.62M Buy
+366,000
New +$9.34M 0.01% 721
2025
Q1 		– Sell
-100,000
Closed -$1.39M – 844
2024
Q4 		$1.39M Buy
+100,000
New +$1.1M ﹤0.01% 806
2024
Q3 		– Sell
-200,000
Closed -$1.86M – 873
2024
Q2 		$1.86M Buy
+200,000
New +$1.81M ﹤0.01% 783

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Adage Capital Partners's ARQT Position: Q2 2026 in Review

Adage Capital Partners increased its Arcutis Biotherapeutics (ARQT) stake by 27% in Q2 2026, buying an estimated $2.33M and bringing the position to 466,000 shares worth $12.2M. The position accounts for 0.02% of the portfolio, ranked #674.

Adage Capital Partners first reported a position in ARQT in Q2 2024 and has held it in 4 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Adage Capital Partners held 466,000 shares of Arcutis Biotherapeutics worth $12.2M as of Q2 2026.
  • Adage Capital Partners bought 100,000 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.33M.
  • Arcutis Biotherapeutics made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #674 holding.
  • Adage Capital Partners first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.